Lithuania vs Trinidad and Tobago: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Lithuania
0.1%
in 2024
Trinidad and Tobago
0.1%
in 2024
Lithuania rank
134th
Trinidad and Tobago rank
134th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Lithuania
- Trinidad and Tobago
How they compare
Lithuania currently reports 0.1% against 0.1% in Trinidad and Tobago, a difference of 0.0%.
Across all 10 years both countries report, Trinidad and Tobago has been ahead every year.
Lithuania ranks 134th and Trinidad and Tobago ranks 134th of 246 countries.
Trinidad and Tobago has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Lithuania | Trinidad and Tobago | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.2% | 0.1% | Trinidad and Tobago |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Lithuania or Trinidad and Tobago?
- Lithuania, at 0.1% against 0.1% in Trinidad and Tobago as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Lithuania and Trinidad and Tobago?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Trinidad and Tobago?
- 10 years are reported by both, from 2015 to 2024.
- How do Lithuania and Trinidad and Tobago rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Lithuania ranks 134th and Trinidad and Tobago ranks 134th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.